Leiter’s Compounding Pharmacy Issues Voluntary Nationwide Recall of Three Product Lots Due to Concerns of Sterility Assurance at Its Independent Testing Vendor

Leiter’s Compounding Pharmacy is voluntarily recalling three lots of its sterile products due to concerns of sterility assurance with Front Range Laboratories, Leiter's Compounding Pharmacy's independent testing laboratory. The following products and lot numbers are subject to the nationwide recall:

    Bevacizumab Lot No. 08052013@1, expiry 11/03/13
    Bevacizumab Lot No. 08052013@4, expiry 11/03/13
     Lidocaine/phenylephrine Lot No. 07302013@6, expiry 10/28/13

The use of a non-sterile injectable product exposes patients to the risk of contracting serious life-threatening infections. Leiter’s Compounding Pharmacy has not received any reports of adverse events or reports of contamination but decided to recall the products following a recent inspection by the FDA of Front Range Laboratories. The FDA investigators observed that methods used by the independent laboratory to assess sterility may have resulted in pharmacies receiving inaccurate laboratory test results. The FDA has concerns that results obtained from the laboratory are not reliable.

These products were dispensed to health care providers between Aug. 5, 2013, and Sept. 2, 2013, nationwide throughout the United States.

Leiter’s Compounding Pharmacy is notifying prescribing physicians by first-class mail, telephone and/or email and is arranging for return of all recalled products. Facilities that have recalled products should stop using them and return them to Leiter’s Compounding Pharmacy, as indicated by the instructions below.

To return product or request assistance related to this recall, users should contact Leiter’s Compounding Pharmacy at 1-800-292-6772, Monday through Friday, between 8:00 a.m. and 5:00 p.m. PST.

Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking or using this drug product.

“After receiving an FDA report of potential testing errors at Front Range, we decided to recall any products associated with the inspection, because we believe it is the most prudent course,” said Charles Leiter, Pharm.D, President of Leiter’s Compounding Pharmacy. “We are working hard to minimize any impact on our valued customers as we continue to provide high-quality compounded medications to patients.”

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

http://www.prweb.com/releases/2013/9/prweb11111124.htm